Blood eosinophil count and prospective annual asthma disease burden: A UK cohort study

The Lancet Respiratory Medicine

Volumn 3, Issue 11, 2015, Pages 849-858

  Price, David B ^a,b   Rigazio, Anna ^b   Campbell, Jonathan D ^c   Bleecker, Eugene R ^d   Corrigan, Christopher J ^e   Thomas, Mike ^f   Wenzel, Sally E ^g   Wilson, Andrew M ^h   Small, Mary Buatti ⁱ   Gopalan, Gokul ⁱ   Ashton, Valerie L ^b   Burden, Anne ^b   Hillyer, Elizabeth V ^b   Kerkhof, Marjan ^b   Pavord, Ian D ^j  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b Research in Real Life   (United Kingdom)

^c UNIVERSITY OF COLORADO   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^g UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^h UNIVERSITY OF EAST ANGLIA   (United Kingdom)

ⁱ TEVA PHARMACEUTICALS   (Israel)

^j UNIVERSITY OF OXFORD   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID; SALBUTAMOL; TERBUTALINE; ANTIASTHMATIC AGENT; ANTIINFECTIVE AGENT; BIOLOGICAL MARKER;

ACUTE DRUG ADMINISTRATION; ACUTE RESPIRATORY TRACT DISEASE; ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; BLOOD ANALYSIS; CHILD; COHORT ANALYSIS; DISEASE CONTROL; DISEASE EXACERBATION; EOSINOPHIL COUNT; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; UNITED KINGDOM; VERY ELDERLY; BLOOD; COST OF ILLNESS; DISEASE COURSE; EOSINOPHIL; GREAT BRITAIN; LEUKOCYTE COUNT; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; REGRESSION ANALYSIS; YOUNG ADULT;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; ANTI-ASTHMATIC AGENTS; ANTI-BACTERIAL AGENTS; ASTHMA; BIOMARKERS; CHILD; COHORT STUDIES; COST OF ILLNESS; DISEASE PROGRESSION; EOSINOPHILS; FEMALE; GREAT BRITAIN; HUMANS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; YOUNG ADULT;

EID: 84961054838     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(15)00367-7     Document Type: Article

References (33)

1. Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008, 178:218-224.
2. Wenzel SE Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012, 18:716-725.
3. Pavord ID, Bafadhel M Exhaled nitric oxide and blood eosinophilia: independent markers of preventable risk. J Allergy Clin Immunol 2013, 132:828-829.
4. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002, 360:1715-1721.
5. Deykin A, Lazarus SC, Fahy JV, et al. Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids. J Allergy Clin Immunol 2005, 115:720-727.
6. Jatakanon A, Lim S, Barnes PJ Changes in sputum eosinophils predict loss of asthma control. Am J Respir Crit Care Med 2000, 161:64-72.
7. Petsky HL, Cates CJ, Lasserson TJ, et al. A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax 2012, 67:199-208.
8. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009, 360:973-984.
9. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012, 380:651-659.
10. Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014, 371:1198-1207.
11. Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013, 368:2455-2466.
12. Ulrik CS Peripheral eosinophil counts as a marker of disease activity in intrinsic and extrinsic asthma. Clin Exp Allergy 1995, 25:820-827.
13. Katz LE, Gleich GJ, Hartley BF, Yancey SW, Ortega HG Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma. Ann Am Thorac Soc 2014, 11:531-536.
14. Wagener AH, de Nijs SB, Lutter R, et al. External validation of blood eosinophils, FENO and serum periostin as surrogates for sputum eosinophils in asthma. Thorax 2015, 70:115-120.
15. Schleich FN, Chevremont A, Paulus V, et al. Importance of concomitant local and systemic eosinophilia in uncontrolled asthma. Eur Respir J 2014, 44:97-108.
16. Hastie AT, Moore WC, Li H, et al. Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthmatic subjects. J Allergy Clin Immunol 2013, 132:72-80.
17. Zeiger RS, Schatz M, Li Q, et al. High blood eosinophil count is a risk factor for future asthma exacerbations in adult persistent asthma. J Allergy Clin Immunol Pract 2014, 2:741-750.
18. Malinovschi A, Fonseca JA, Jacinto T, Alving K, Janson C Exhaled nitric oxide levels and blood eosinophil counts independently associate with wheeze and asthma events in National Health and Nutrition Examination Survey subjects. J Allergy Clin Immunol 2013, 132:821-827. e1-5.
19. Tran TN, Khatry DB, Ke X, Ward CK, Gossage D High blood eosinophil count is associated with more frequent asthma attacks in asthma patients. Ann Allergy Asthma Immunol 2014, 113:19-24.
20. Optimum Patient Care Research Database Optimum Patient Care, (accessed Oct 8, 2015). http://www.optimumpatientcare.org/opcrd.
21. Clinical Practice Research Datalink Medicines & Healthcare Products Regulatory Agency, (accessed Oct 8, 2015). http://www.cprd.com/home.
22. Full blood count UK National Health Service, (accessed June 27, 2015). http://www.pathology.leedsth.nhs.uk/pathology/ClinicalInfo/Haematology/FullBloodCount.aspx.
23. Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009, 180:59-99.
24. 2012 update: global strategy for asthma management and prevention Global Initiative for Asthma, (accessed June 27, 2015). http://www.ginasthma.org/documents/5/documents_variants/37.
25. Castro M, Wenzel SE, Bleecker ER, et al. Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med 2014, 2:879-890.
26. Khatry DB, Gossage DL, Geba GP, et al. Discriminating sputum-eosinophilic asthma: accuracy of cutoffs in blood eosinophil measurements versus a composite index, ELEN. J Allergy Clin Immunol 2015, 136:812-814.
27. British guideline on the management of asthma: a national clinical guideline (SIGN 141) British Thoracic Society, Scottish Intercollegiate Guidelines NetworkScottish Intercollegiate Guidelines Network, (accessed June 27, 2015). http://www.sign.ac.uk/pdf/SIGN141.pdf.
28. Wardlaw AJ, Brightling C, Green R, Woltmann G, Pavord I Eosinophils in asthma and other allergic diseases. Br Med Bull 2000, 56:985-1003.
29. Telenga ED, Kerstjens HA, Ten Hacken NH, Postma DS, van den Berge M Inflammation and corticosteroid responsiveness in ex-, current- and never-smoking asthmatics. BMC Pulm Med 2013, 13:58.
30. Zhang XY, Simpson JL, Powell H, et al. Full blood count parameters for the detection of asthma inflammatory phenotypes. Clin Exp Allergy 2014, 44:1137-1145.
31. Nair P What is an "eosinophilic phenotype" of asthma?. J Allergy Clin Immunol 2013, 132:81-83.
32. Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 2015, 3:435-442.
33. Szefler SJ, Wenzel S, Brown R, et al. Asthma outcomes: biomarkers. J Allergy Clin Immunol 2012, 129:S9-23.